KaloBios

KaloBios Pharmaceuticals, Inc.,

a private company based in South San Francisco, California, is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.

Currently, KaloBios is conducting three clinical development programs with a focus on respiratory diseases and cancer. Within each of these programs, KaloBios focuses primarily on patient-targeted drug indications where a prognostic or diagnostic is used to prescreen patients to determine those most likely to benefit from a given treatment.

KaloBios has raised $85 million in four rounds of venture funding since the company’s founding in 2001. Major shareholders include MPM Capital, Sofinnova Ventures, Alloy Ventures, GBS Venture Partners, 5 AM Ventures, Bio 1 Capital, Mitsubishi UFJ Capital, Genzyme Ventures, Baxter International, Inc., and Development Bank of Japan.